Organon & Co. (NYSE:OGN) Given Sell (D+) Rating at Weiss Ratings

Organon & Co. (NYSE:OGN - Get Free Report)'s stock had its "sell (d+)" rating restated by investment analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Organon & Co. Stock Up 1.3%

Organon & Co. stock opened at $9.17 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The stock's fifty day simple moving average is $9.92 and its 200-day simple moving average is $9.90. The firm has a market capitalization of $2.38 billion, a P/E ratio of 3.41, a P/E/G ratio of 0.83 and a beta of 0.63. Organon & Co. has a twelve month low of $8.01 and a twelve month high of $19.05.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter in the previous year, the firm posted $1.12 earnings per share. The company's revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Institutional Trading of Organon & Co.

Several hedge funds and other institutional investors have recently bought and sold shares of OGN. Douglas Lane & Associates LLC boosted its position in Organon & Co. by 19.0% in the 2nd quarter. Douglas Lane & Associates LLC now owns 315,952 shares of the company's stock valued at $3,058,000 after buying an additional 50,393 shares during the last quarter. Triumph Capital Management raised its holdings in shares of Organon & Co. by 109.1% during the 2nd quarter. Triumph Capital Management now owns 90,342 shares of the company's stock valued at $875,000 after purchasing an additional 47,127 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Organon & Co. by 42.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock valued at $289,000 after purchasing an additional 5,758 shares in the last quarter. M&T Bank Corp raised its holdings in shares of Organon & Co. by 3.4% during the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company's stock valued at $833,000 after purchasing an additional 1,854 shares in the last quarter. Finally, WBI Investments LLC bought a new position in Organon & Co. in the 1st quarter worth $946,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.